Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and Biocon's recent dealmaking with Mylan and Pfizer in part one of this interview. In this second part, she discusses the regulatory challenges for biosimilars.
You may also be interested in...
As New Biosimilars Roll Out, Indian Biotech Group Raises Quality Concerns
Leading biotech group ABLE cautioned the government that India should not become a dumping ground for low-quality biosimilar products. The group pointed at several concerns related to Cipla’s latest launch of Enbrel copies.
Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News
Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.
Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference
SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24